TAPUR: assessing commercially available targeted therapies in solid tumors [Video]

Deepti Behl, MD, Sutter Sacramento Medical Center, Sacramento, CA, gives an overview of the Phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study (NCT02693535), which aims to evaluate commercially available targeted agents in solid tumors. There are many cohorts being assessed, with AKT1/3-mutated tumors making up one cohort. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.